Table 1. Clinical activity of PD-1 and PD-L1 inhibitors in non-small cell lung cancer.

Agent	Setting	No. patients evaluable for response	RR (%)	SD ≥24 weeks (%)	PFS rate at 24 weeks (%)	OS (mo)
PD-1
Nivolumab	Phase I
	All patients	76	18	7	26	9.6
	Squamous	18	33	0	33	9.2
	Non-squamous	56	12	9	22	9.6
Lambrolizumab	Phase I	Ongoing
PD-L1
BMS936559	Phase I
	All patients	49	10	12	31	NM
	Squamous	13	8	23	43
	Non-squamous	36	11	8	26
MPDL3280A	Phase I
	All patients	41	22	12	46	NM
	Squamous	9	33	11	44
	Non-squamous	31	19	13	44
Medi-4736	Phase I	Ongoing

Abbreviations: RR, response rate; SD, stable disease; PFS, progression-free survival; OS, overall survival.